GO:1990705Ontology (GO BP)GO biological process · ~5 member genes
Q-omics provides the Cholangiocyte proliferation (GO:1990705) pathway profile, scoring each patient from the combined activity of its roughly 5 member genes. Pathway activity is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, the pathway is differentially active in 12, with the highest sampling consensus in KIRC. Additionally, pathway RNA activity shows 30,740 significant cross-omics associations, again with the highest sampling consensus in KIRC. Together, these results highlight UVM, and KIRC as cancer lineages where the pathway shows reproducible signals across outcome, tissue activity, and molecular association analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns. Pathway-against-pathway and pathway-against-mutation comparisons are not available for ontology entities.
Survival associations
This table summarizes Cholangiocyte proliferation survival associations by molecular data type. RNA-level pathway activity shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each layer.
This table ranks reproducible pathway activity–survival associations across cancer types. High Cholangiocyte proliferation activity shows favorable associations in UVM, KIRP, LGG, LIHC and CESC, but unfavorable associations in MESO. In the UVM Kaplan–Meier curve the low-activity group declines faster, consistent with the favorable association (log-rank p < 0.001). UVM ranks highest by sampling consensus for Cholangiocyte proliferation.
This table summarizes Cholangiocyte proliferation tumor–normal activity differences by data type. RNA-level activity shows significant tumor–normal differences in 12 cancer types, while mass-spec protein activity shows differences in 3. The strongest signals are in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal activity differences for the pathway. A positive fold-change indicates higher activity in tumor tissue. The pathway shows consistently lower tumor activity across KIRC, BLCA, KICH, LUAD, KIRP and LUSC. In the KIRC box plot, normal samples show higher pathway activity than tumor samples (log2 FC = −0.136, t-test p < 0.001).
This table shows molecular features associated with Cholangiocyte proliferation pathway activity in patient tissues and cancer cell lines. In patient samples, pathway activity is most strongly linked to RNA and protein features, with the largest associated set in KIRC. In cancer cell lines, RNA-expression features and functional dependencies dominate, with the largest set in BONE.